TABLE 1.
MIC values obtained for different M. kansasii subtypes (n = 23) and clinical isolates from Poland (n = 62) with broth microdilution methodc
| Type | NTM disease | RIF |
CLR |
INH |
EMB |
STR |
AMK |
SXTb |
RFB |
MXF |
LZD |
CIP |
DOX |
ETO |
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | ||
| Individual types (n = 23) | ||||||||||||||||||||||||||||||||||||||||
| I (n = 5) | Yes | 0.25 | 0.25 | 0.25/0.25 | 0.12–>64 | 0.12 | 0.12/>64 | 2 | 2 | 2/2 | 16–>16 | >16 | >16/>16 | 4–>64 | 8 | 8/>64 | 1–4 | 2 | 2/4 | <0.12–0.5 | <0.12 | <0.12/0.5 | <0.25 | <0.25 | <0.25/<0.25 | <0.12 | <0.12 | <0.12/<0.12 | 1–2 | 2 | 2/2 | 1–4 | 1.5 | 2/4 | 4–8 | 4 | 4/8 | <0.3–0.6 | <0.3 | <0.3/0.6 |
| I (n = 1) | No | 0.25 | 0.25 | 0.25 | 0.12 | 0.12 | 0.12 | 2 | 2 | 2 | 16 | 16 | 16 | 8 | 8 | 8 | 2 | 2 | 2 | <0.12 | <0.12 | <0.12 | <0.25 | <0.25 | <0.25 | <0.12 | <0.12 | <0.12 | <1 | <1 | <1 | 1 | 1 | 1 | 4 | 4 | 4 | <0.3 | <0.3 | <0.3 |
| I/II (n = 1) | Yes | 0.5 | 0.5 | 0.5 | 0.25 | 0.25 | 0.12 | 2 | 2 | 2 | >16 | >16 | >16 | 4 | 4 | 4 | 2 | 2 | 2 | 0.12 | 0.12 | 0.12 | <0.25 | <0.25 | <0.25 | <0.12 | <0.12 | <0.12 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 4 | <0.3 | <0.3 | <0.3 |
| IIb (n = 1) | Yes | 1 | 1 | 1 | 0.5 | 0.5 | 0.25 | 2 | 2 | 2 | >16 | >16 | >16 | 8 | 8 | 8 | 4 | 4 | 4 | 0.12 | 0.12 | 0.12 | <0.25 | <0.25 | <0.25 | <0.12 | <0.12 | <0.12 | 2 | 2 | 2 | 1 | 1 | 1 | 8 | 8 | 8 | <0.3 | <0.3 | <0.3 |
| IIb (n = 1) | No | 0.5 | 0.5 | 0.5 | 0.25 | 0.25 | 0.5 | 1 | 1 | 1 | >16 | >16 | >16 | 4 | 4 | 4 | 2 | 2 | 2 | 0.12 | 0.12 | 0.12 | <0.25 | <0.25 | <0.25 | <0.12 | <0.12 | <0.12 | 2 | 2 | 2 | 0.5 | 0.5 | 0.5 | 4 | 4 | 4 | <0.3 | <0.3 | <0.3 |
| II (n = 2) | Yes | 0.25–1 | 1.5 | 1/2 | 0.5–1 | 0.75 | 0.5/1 | 1–2 | 1.5 | 1/2 | >16 | >16 | >16/>16 | 4–8 | 6 | 4/8 | 2–8 | 5 | 2/8 | 0.12–2 | 1 | 0.12/0.2 | <0.25 | <0.25 | <0.25/<0.25 | <0.12–0.25 | 0.19 | <0.12/0.25 | 2–4 | 3 | 2/4 | 1 | 1 | 1/1 | 8 | 8 | 8/8 | <0.3–0.6 | 0.45 | <0.3/0.6 |
| II (n = 4) | No | 0.25–1 | 1 | 1/1 | 0.12–05 | 0.19 | 0.12/05 | 1 | 1 | 1/1 | 16–>16 | >16 | >16/>16 | 4–16 | 12 | 8/16 | 2–8 | 3 | 2/8 | <0.12 | <0.12 | <0.12/<0.12 | <0.25 | <0.25 | <0.25/<0.25 | <0.12 | <0.12 | <0.12/<0.12 | 2–4 | 2 | 2/4 | 0.5–2 | 1.5 | 1/2 | 4–16 | 8 | 8/16 | <0.3 | <0.3 | <0.3/<0.3 |
| III (n = 3) | No | <0.12–0.5 | 0.12 | 0.12/0.5 | <0.06–0.12 | 0.12 | 0.12/0.12 | 1–2 | 1 | 1/2 | 16–>16 | >16 | >16/>16 | 4–8 | 4 | 4/8 | <1–4 | 2 | 2/4 | <0.12–0.5 | <0.12 | <0.12/0.5 | <0.25 | <0.25 | <0.25/<0.25 | <0.12 | <0.12 | <0.12/<0.12 | <1–2 | 2 | 2/2 | 0.5–2 | 1 | 1/2 | 1–4 | 2 | 2/4 | <0.3 | <0.3 | <0.3/<0.3 |
| IV (n = 2) | No | <0.12 | <0.12 | <0.12/<0.12 | <0.06–0.06 | >0.06 | <0.06/0.06 | 1–2 | 1.5 | 1/2 | 16–>16 | >16 | 16/>16 | 4 | 4 | 4/4 | 2–4 | 3 | 2/4 | 0.12 | 0.12 | 0.12/0.12 | <0.25 | <0.25 | <0.25/<0.25 | <0.12 | <0.12 | <0.12/<0.12 | <1–2 | 1.5 | <1–2 | 0.5–2 | 1.25 | 0.5/2 | 2–4 | 3 | 2/4 | <0.3 | <0.3 | <0.3/<0.3 |
| V (n = 2) | No | <0.12–0.5 | 0.31 | <0.12/0.5 | <0.06–0.12 | 0.09 | <0.06/0.12 | <0.25–2 | 1.1 | <0.25/2 | 4 | 4 | 4/4 | 4 | 4 | 4/4 | 2 | 2 | 2/2 | 0.12 | 0.12 | 0.12/0.12 | <0.25 | <0.25 | <0.25/<0.25 | <0.12–0.25 | 0.06 | <0.12/0.25 | 2 | 2 | 2/2 | 1–2 | 1.5 | 1/2 | 4 | 4 | 4/4 | <0.3 | <0.3 | <0.3/<0.3 |
| VI (n = 1) | No | 0.25 | 0.25 | 0.25 | 0.12 | 0.12 | 0.12 | 2 | 2 | 2 | 16 | 16 | 16 | 8 | 8 | 8 | 1 | 1 | 1 | <0.12 | <0.12 | <0.12 | <0.25 | <0.25 | <0.25 | <0.12 | <0.12 | <0.12 | 2 | 2 | 2 | 1 | 1 | 1 | 8 | 8 | 8 | <0.3 | <0.3 | <0.3 |
| Clinical isolates (n = 62) | ||||||||||||||||||||||||||||||||||||||||
| I (n = 39) | Yes | <0.12–1 | 0.25 | 0.25/1 | <0.6–0.5 | 0.12 | 0.12/0.5 | 1–4 | 2 | 2/4 | 8–>16 | >16 | >16/>16 | 2–>64 | 8 | 8/16 | <1–8 | 2 | 2/4 | <0.12–1 | <0.12 | <0.12/0.12 | <0.25 | <0.25 | <0.25 | <0.12–0.5 | <0.12 | <0.12/0.25 | <1–8 | 2 | 2/4 | 0.25–8 | 1 | 1/4 | 1–>16 | 8 | 8/>16 | <0.3–1.2 | <0.3 | <0.3/0.6 |
| I (n = 22) | No | 0.25–1 | 0.25 | 0.25/1 | 0.12–0.5 | 0.25 | 0.25/0.25 | 1–4 | 2 | 2/2 | 8–>16 | >16 | >16/>16 | 1–64 | 8 | 8/16 | <1–8 | 2 | 2/8 | <0.12–0.5 | <0.12 | <0.12/0.25 | <0.25 | <0.25 | <0.25 | <0.12–0.5 | <0.12 | <0.12/0.25 | <1–4 | 2 | 2/4 | 0.25–8 | 1 | 1/4 | 1–>16 | 8 | 8/16 | <0.3–0.6 | <0.3 | <0.3/0.3 |
| II (n = 1) | No | 0.5 | 0.5 | 0.5 | 0.12 | 0.12 | 0.12 | 1 | 1 | 1 | 16 | 16 | 16 | 2 | 2 | 2 | <1 | <1 | <1 | <0.12 | <0.12 | <0.12 | <0.25 | <0.25 | <0.25 | <0.12 | <0.12 | <0.12 | <1 | <1 | <1 | 0.25 | 0.25 | 0.25 | 2 | 2 | 2 | <0.3 | <0.3 | <0.3 |
| Total | <0.12–1 | 0.25 | 0.25/1 | <0.6–0.5 | 0.25 | 0.25/0.5 | 1–4 | 2 | 2/2 | 8–>16 | >16 | >16/>16 | 1–>64 | 8 | 8/16 | <1–8 | 2 | 2/4 | <0.12–1 | <0.12 | <0.12/0.12 | <0.25 | <0.25 | <0.25/<0.25 | <0.12–0.5 | <0.12 | <0.12/0.25 | <1–8 | 2 | 2/4 | 0.25–8 | 1 | 1/4 | 1–>16 | 8 | 8/>16 | <0.3–1.2 | <0.3 | <0.3/0.6 | |
| Total (n = 85) | <0.12–1 | 0.25 | 0.25/1 | <0.06–>64 | 0.25 | 0.25/0.5 | <0.25–4 | 2 | 2/2 | 4–>16 | >16 | >16/>16 | 1–>64 | 8 | 8/16 | <1–8 | 2 | 2/4 | <0.12–2 | <0.12 | <0.12/0.25 | <0.25 | <0.25 | <0.25/<0.25 | <0.12–0.5 | <0.12 | <0.12/0.25 | <1–8 | 2 | 2/4 | 0.25–8 | 1 | 1/4 | 1–>16 | 8 | 8/16 | <0.3–1.2 | <0.3 | <0.3/0.6 | |
| No. (%) of resistant isolates (n = 85) | 0 (0) | 1 (1.2) | NAa | 83 (97.6) | NA | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (20) | NA | NA | |||||||||||||||||||||||||||
a
NA, not applicable. Critical drug concentration not available in CLSI guidelines.
b
For SXT (ratio of 1:19 for trimethoprim to sulfamethoxazole), the concentration of trimethoprim is indicated.
c
R, MIC ranges; M, median MIC.